Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1476-1484

  Goh, B C ^a   Ratain, M J ^a   Bertucci, D ^a   Smith, R ^a   Mani, S ^a   Vogelzang, N J ^a   Schilsky, R L ^a   Hutchison, M ^a   Smith, M ^a   Averbuch, S ^a   Douglass, E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLEVITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED DISEASE; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035281914     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1476     Document Type: Article

References (30)

1. Folate-based thymidylate synthase inhibitors as anticancer drugs
2. Clinical pharmacokinetics of antitumor antifolates
3. Antifolates in clinical development
4. A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in mice
5. Biochemical effects of a quinozoline inhibitor of thymidylate-synthase, CB 3717, on human lymphoblastoid cells
6. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5, 8-dideafolic acid, CB 3717
7. The clinical pharmacokinetics of the novel antifolate N10-propargyl-5, 8-dideafolic acid (CB3717)
8. Quinozoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency
9. Tomudex (ZD1694): From concept to care, a programme in rational drug discovery
10. 1C1 D1694, a quinozoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study
11. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors
12. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines
13. Resistance to Tomudex (ZD1694): Multifactorial in human breast and colon carcinoma cell lines
14. Folate antagonists as therapeutic agents
15. Nonpolyglutamatable antifolates as inhibitors of thymidylate synthase (TS) and potential antitumor agents
16. Design and synthesis of potent non-polyglutamatable quinozoline antifolate thymidylate synthase inhibitors
17. ZD9331, the design and synthesis of a novel non-polyglutamatable TS inhibitor
18. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water soluble, non-polyglutamatable, quinozoline-based inhibitor of thymidylate synthase
19. The antitumor activity of ZD9331, a non-polyglutamatable quinozoline thymidylate synthase inhibitor
20. Modulation of antimetabolite effects. Effects of thymidine on the efficacy of the quinozoline-based thymidylate synthetase inhibitors, CB3717
21. Accelerated titration designs for phase I clinical trials in oncology
22. Analysis and selection of variables in linear regression
23. Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks
24. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeks
25. Evaluation of the factors influencing the clearance of the novel thymidylate synthase inhibitor ZD9331
26. The renal effects of the water-soluble, non-folylpolyglutamyl synthetase-dependent thymidylate synthase inhibitor ZD 9331 in mice
27. Body surface area as a basis for dosing of anticancer drugs: Science, myth, or habit?
28. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days
29. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged infusion in patients with solid tumors